Werewolf Therapeutics, Inc.

HOWL

$0.34

$-0.01 (-3.57%)

Closed

Loading chart...

IndexN/A

Market Cap0.02B

Enterprise Value-0.02B

Income$-0.02B

Sales$0.00B

EmployeesN/A

P/E-0.27

P/SN/A

P/B1.18

P/C-0.48

EV/EBITDA0.36

EV/SalesN/A

EPS (ttm)-1.24

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.68M

Shs Outstand0.05B

Change-3.57%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

May 704:05PMWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates(globenewswire.com)

Mar 2707:00AMWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates(globenewswire.com)

Feb 2404:09PMWerewolf Therapeutics Announces Plan to Explore Strategic Alternatives(globenewswire.com)

Feb 2001:57AMAnalysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75

Insider Trading

View All

Insider

Type

Price

Value

Date

EVNIN LUKE

Sell

157.1K

$0.30

$47K

Jun 29, 26

RA CAPITAL MANAGEMENT, L.P.

Sell

389.2K

$0.35

$136K

Jun 17, 26

RA CAPITAL MANAGEMENT, L.P.

Sell

159.1K

$0.40

$64K

Jun 12, 26

RA CAPITAL MANAGEMENT, L.P.

Sell

345.2K

$0.37

$128K

Jun 9, 26

EVNIN LUKE

Sell

76.9K

$0.37

$28K

Jun 9, 26

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

CEO: Daniel J. HicklinEmployees: 46werewolftx.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.89M	$19.94M	$16.40M	N/A	N/A	N/A
Cost of Revenue	$1.81M	$1.76M	$2.51M	N/A	$777.00K	$463.00K
Gross Profit	$71.00K	$18.18M	$13.89M	N/A	$-777.00K	$-463.00K
Gross Margin	3.77%	91.15%	84.70%	0.00%	0.00%	0.00%
Operating Expenses	$73.67M	$58.68M	$69.95M	$50.09M	$21.63M	$9.47M
Operating Income	$-73.59M	$-40.50M	$-56.06M	$-50.09M	$-22.40M	$-9.94M
Operating Margin	-3904.19%	-203.09%	-341.78%	0.00%	0.00%	0.00%
Net Income	$-70.52M	$-37.37M	$-53.81M	$-49.98M	$-14.94M	$-10.99M
Net Margin	-3740.85%	-187.37%	-328.09%	0.00%	0.00%	0.00%
EPS (Basic)	$-1.63	$-1.05	$-1.86	$-10.94	$-0.98	$-0.38
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A

Werewolf Therapeutics, Inc.

Insider Trading

Discover more